ArticleCell proliferation2026
iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice.
Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
NK cells exhibit inherently short persistence in vivo. Allo-NK cells trigger host immune rejection in immune-competent patients. Lymphodepletion is a conventional approach for mitigating allogeneic rejection of therapeutic NK cells, which brings host immune suppression and infection risks. To address these problems, we test the concept of engrafting iNK progenitor (iNKP) cells derived from human induced pluripotent stem cells (iPSC) to achieve generating iNK cells in vivo in unconditioned host-immune humanised mice without the requirement for prior lymphodepleting chemotherapy or total body irradiation. Our results showed that a single low-dose infusion of iNKP cells successfully engrafted and continuously produced mature iNK cells in unconditioned B-NDG hIL15 mice. Furthermore, the iPSC-derived iNKP cells survived in the presence of autologous PBMC-humanised mice and generated mature iNK cells. This study provides evidence that autologous iPSC-derived iNKP cells have the application potential for treating the same individual without the preceding necessity of lymphodepletion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.